Financial Data and Key Metrics Changes - In Q4 2025, total revenue grew 14% year-over-year to $44.6 million, with a sequential increase of 16% [7][27] - For the full year 2025, total revenue reached $160 million, representing a 4% growth over 2024 [7][30] - Non-GAAP gross margin improved to 40% in Q4 2025, up from 31% in Q4 2024, and for the full year, it was also 40%, compared to 33% in 2024 [31][24] - Non-GAAP operating expenses decreased to $56.2 million in Q4 2025, down 18% year-over-year, and for the full year, they were $229.9 million, down from $289.2 million in 2024 [32][24] - Cash burn improved from $214 million in 2023 to $105 million in 2025, with approximately $280 million in cash and investments at year-end [25][34] Business Line Data and Key Metrics Changes - Consumable revenue in Q4 2025 increased 15% year-over-year to $21.6 million, driven by an increase in the installed base and consistent system utilization [27][28] - Instrument revenue rose 13% in Q4 to $17.3 million, primarily due to increased shipments of Vega systems [28] - For the full year 2025, consumables revenue increased 16% to $82 million, while instrument revenue decreased 18% to $53.8 million [30] Market Data and Key Metrics Changes - Revenue from the Americas increased 3% to $20.7 million in Q4 2025, while Asia Pacific revenue rose 4% to $9.3 million, and EMEA revenue surged 45% to $14.6 million [29][10] - EMEA's strong growth was attributed to increased Vega instrument shipments and higher Revio consumables as clinical customers transitioned from pilot testing to broader adoption [11][29] Company Strategy and Development Direction - The company aims to enhance the economics of HiFi sequencing through the launch of SparkNex and multi-use smart cells, targeting increased market penetration [37] - Focus areas include accelerating clinical adoption in rare disease, oncology, and carrier screening, as well as enabling population-scale sequencing studies [37] - The company plans to leverage AI to unlock biological insights from multi-omic HiFi data [37] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued growth in clinical markets, particularly in rare disease and whole genome sequencing, despite a challenging academic funding environment [11][54] - The outlook for 2026 projects revenue between $165 million and $180 million, representing approximately 8% growth at the midpoint [34] - Management expects non-GAAP gross margin to improve by 100-400 basis points in 2026, driven by a higher consumables mix and the introduction of SparkNex [35] Other Important Information - The company sold its short-read sequencing assets for net proceeds of approximately $48 million, strengthening its balance sheet and extending its cash runway [26] - The company is committed to supporting existing customers during the transition period following the divestment of short-read assets [26] Q&A Session Summary Question: What should we expect for Revio pull-through and consumables growth? - Management expects SparkNex to lower sample costs, likely increasing utilization and expanding market share, while maintaining pull-through in the range of $225K-$250K [41][43] Question: What is the outlook for clinical growth outside the U.S.? - Management sees strong growth in clinical markets, particularly in EMEA, with significant movement from pilot phases to production [53] Question: Where are the biggest opportunities for OpEx reduction? - Management plans to focus on managing G&A expenses and R&D while continuing to reduce production costs through insourcing [66][68] Question: What impact will the short-read divestment have on costs? - Management indicated that while there won't be substantial additional costs taken out immediately, the divestment will provide a tailwind to gross margin over time [72] Question: How does long-read sequencing compare to standard care in terms of cost? - Long-read sequencing is expected to provide better diagnostic yield, faster turnaround times, and lower overall costs by consolidating multiple tests into one [74]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue grew 14% year-over-year to $44.6 million, with a sequential increase of 16% [7][26] - For the full year 2025, total revenue reached $160 million, representing a 4% growth over 2024 [7][30] - Non-GAAP gross margin improved to 40% in Q4 2025, up from 31% in Q4 2024, and also increased from 33% in 2024 to 40% in 2025 [31][23] - Non-GAAP operating expenses decreased from $355 million in 2023 to $230 million in 2025, a 35% reduction [23][32] - Cash burn improved from $214 million in 2023 to $105 million in 2025, representing a 51% improvement [24] Business Line Data and Key Metrics Changes - Consumable revenue in Q4 2025 increased 15% year-over-year to $21.6 million, driven by an increase in the installed base and consistent system utilization [26][30] - Instrument revenue increased 13% in Q4 2025 to $17.3 million, primarily due to an increase in Vega systems [27] - For the full year 2025, consumables revenue grew 16% to $82 million, while instrument revenue decreased 18% to $53.8 million [30] Market Data and Key Metrics Changes - In Q4 2025, Americas revenue increased 3% to $20.7 million, Asia Pacific revenue increased 4% to $9.3 million, and EMEA revenue surged 45% to $14.6 million [10][29] - EMEA's strong growth was attributed to increased Vega instrument shipments and higher Revio consumables as clinical customers shifted to broader clinical adoption [11][29] Company Strategy and Development Direction - The company aims to improve the economics of HiFi sequencing through the launch of SparkNex and multi-use smart cells [38] - Focus on accelerating clinical adoption in rare disease, oncology, and carrier screening, while enabling population-scale sequencing studies [38] - The strategy includes leveraging AI to unlock biological insights and driving innovation in sequencing technology [38] Management's Comments on Operating Environment and Future Outlook - Management expects 2026 revenue to be in the range of $165 million to $180 million, representing approximately 8% growth at the midpoint [11][34] - The company anticipates continued pressure from the academic funding environment, particularly in the Americas, impacting capital spending [34][35] - Management is optimistic about the growth in clinical markets, especially in EMEA, despite the challenges in the academic sector [53] Other Important Information - The company sold its short-read sequencing assets for net proceeds of approximately $48 million, strengthening its balance sheet [25] - The introduction of SparkNex is expected to enhance gross margins and improve the overall financial profile [21][23] Q&A Session Summary Question: What should we expect OUS to do this year from a clinical growth perspective? - Management noted strong growth in clinical markets, particularly in rare disease and whole genome sequencing, especially in EMEA, with customers moving from pilot phases to production [53] Question: Where's the biggest opportunity to reduce OpEx spending this year? - Management indicated a focus on managing G&A expenses and R&D while maintaining critical programs, with a goal to reduce non-headcount-related spending [66] Question: Did you see any budget flush, particularly from Europe in full Q25? - Management did not observe significant budget flush but noted some opportunistic purchasing [51][52]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue grew 14% year-over-year to $44.6 million, with a sequential increase of 16% [5][25] - For the full year 2025, total revenue reached $160 million, representing a 4% growth over 2024 [5][29] - Non-GAAP gross margin improved to 40% in Q4 2025, up from 31% in Q4 2024, and for the full year, it was also 40%, compared to 33% in 2024 [30][22] - Non-GAAP operating expenses decreased to $56.2 million in Q4 2025, down 18% year-over-year, and for the full year, they were $229.9 million, down from $289.2 million in 2024 [31][22] Business Line Data and Key Metrics Changes - Consumable revenue in Q4 2025 increased 15% year-over-year to $21.6 million, driven by a growing installed base and consistent system utilization [25][6] - Instrument revenue rose 13% in Q4 2025 to $17.3 million, primarily due to increased shipments of Vega systems [26] - For the full year 2025, consumables revenue increased 16% to $82 million, while instrument revenue decreased 18% to $53.8 million [29] Market Data and Key Metrics Changes - Revenue from the Americas increased 3% to $20.7 million in Q4 2025, while Asia Pacific revenue grew 4% to $9.3 million, and EMEA revenue surged 45% to $14.6 million [27][28] - The strong growth in EMEA was attributed to increased clinical adoption and higher shipments of Vega instruments [28] Company Strategy and Development Direction - The company aims to improve the economics of HiFi sequencing through the launch of SparkNex and multi-use smart cells, targeting increased market penetration [37] - Focus areas include accelerating clinical adoption in rare disease, oncology, and carrier screening, as well as enabling population-scale sequencing studies [37] - The company plans to leverage AI to unlock unique biological insights from multi-omic HiFi data [37] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued growth in clinical markets, particularly in rare disease and whole genome sequencing, despite a challenging academic funding environment [9][52] - The outlook for 2026 projects revenue between $165 million and $180 million, representing approximately 8% growth at the midpoint [33] - Management expects non-GAAP gross margin to improve by 100-400 basis points in 2026, driven by a higher consumables mix and the introduction of SparkNex [34] Other Important Information - The company ended 2025 with approximately $280 million in cash and investments, down from $389.9 million at the end of 2024 [23][33] - The recent sale of short-read sequencing assets for approximately $48 million is expected to strengthen the balance sheet and extend the cash runway [24] Q&A Session Summary Question: What should we expect OUS to do this year from a clinical growth perspective? - Management noted strong growth in clinical markets, particularly in EMEA, with many customers moving from pilot testing to broader clinical adoption [52] Question: What is the biggest opportunity to reduce OpEx spending this year? - Management indicated a focus on managing G&A expenses and R&D while maintaining funding for critical programs [66] Question: Did you see any budget flush, particularly from Europe in full Q25? - Management did not observe significant budget flush but noted some opportunistic purchasing [51]

Core Insights - PacBio has launched an enhanced suite of PureTarget products aimed at the high-throughput carrier screening market, consolidating multiple specialized assays into a single scalable solution for inherited disease screening [1][5] Group 1: Product Features - The updated PureTarget solutions utilize PacBio's HiFi sequencing technology to address challenging genes associated with inherited conditions, allowing for a more comprehensive carrier screening approach [1][3] - The new product line includes 24- and 96-sample kit formats, designed to meet various laboratory needs and streamline workflows [3][4] - The upgraded kits can process up to 100,000 samples annually on a single Revio system, making them suitable for large-scale screening initiatives [4] Group 2: Market Context - Recent research indicates that up to 71% of individuals carry at least one pathogenic variant, underscoring the increasing relevance of carrier screening in family planning [2] - The demand for carrier screening is growing across commercial labs, health systems, and government-funded programs globally, highlighting the need for efficient and comprehensive testing solutions [2][5] Group 3: Strategic Implications - PacBio's entry into the carrier screening market reflects a commitment to simplifying complex genomic testing and expanding access to comprehensive screening worldwide [5] - The consolidation of fragmented workflows into a single test is expected to enhance operational efficiency and clinical outcomes for laboratories [5]